Lilly Moves Closer To NDA Filing For RET Inhibitor In NSCLC

 
• By Joseph Haas

Lilly hopes to bring Loxo’s tissue-agnostic RET inhibitor selpercatinib to market in 2020.

DNA strand and Cancer Cell Oncology Research Concept 3D rendering - Illustration
Lilly is developing Loxo's technology to target cancer on a genetic basis

More from Strategy

More from Business